cyclophosphamide + fluorouracil + methotrexate + prednisone

This is a combination chemotherapy regimen consisting of four drugs: cyclophosphamide, fluorouracil (5-FU), methotrexate, and prednisone. Each component has a distinct mechanism of action: - Cyclophosphamide is an alkylating agent that interferes with DNA replication and transcription by cross-linking DNA strands. - Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - Methotrexate is also an antimetabolite that inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication. - Prednisone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; in oncology regimens it can induce apoptosis in certain cancer cells. This combination has been used as part of multi-agent chemotherapy protocols for various solid tumors including breast cancer, lung cancer, ovarian cancer, and gastrointestinal cancers. The regimen aims to maximize tumor cell kill by combining agents with different mechanisms while managing toxicity profiles[1][2][6].

Other names

CMFPCMF-P